Adverse Effect Profile and Effectiveness of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) - A Prospective Real-world Setting Study.
Effectiveness
SGLT2i
real world
safety
type 2 diabetes
Journal
Indian journal of endocrinology and metabolism
ISSN: 2230-8210
Titre abrégé: Indian J Endocrinol Metab
Pays: India
ID NLM: 101555690
Informations de publication
Date de publication:
Historique:
entrez:
25
4
2019
pubmed:
25
4
2019
medline:
25
4
2019
Statut:
ppublish
Résumé
Clinical trials have shown promising results in terms of glycemic control and weight reduction with the use of sodium glucose co-transporter 2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2DM). However, real-world evidence from standard clinical practice especially from Asia is still limited. The aim of this study was to evaluate the safety and effectiveness of SGLT2i in patients with T2DM in real-world setting. This was a prospective observational longitudinal study involving consecutive patients with T2DM, initiated on SGLT2i from 1 April 2015 to 31 March 2016. The adverse effects and metabolic parameters were evaluated at 3 monthly intervals up to 1 year. Total 486 patients were initiated on SGLT2i. At baseline, mean age, glycosylated haemoglobin (HbA1c), and weight was 51.03 ± 9.82 years, 8.76 ± 1.59%, and 89.32 ± 16.04 kg, respectively. Data of 388 patients were available at 6 months of follow-up for analysis of adverse effects profile. About 38.6% patients experienced adverse effects. Genitourinary tract infection was the most common adverse effect (20.6%) followed by generalized weakness (10.5%). Significant reduction in mean weight and HbA1c reduction seen at 6 months ( In this real-world study of patients with T2DM living in hot climate, use of SGLT2i was associated with adverse effects in higher proportion of patients than those reported in clinical trials, but effectiveness was comparable. Patient guidance regarding adequate hydration and hygiene can maximize the benefits of this promising class of drugs.
Sections du résumé
BACKGROUND
BACKGROUND
Clinical trials have shown promising results in terms of glycemic control and weight reduction with the use of sodium glucose co-transporter 2 inhibitors (SGLT2i) in type 2 diabetes mellitus (T2DM). However, real-world evidence from standard clinical practice especially from Asia is still limited. The aim of this study was to evaluate the safety and effectiveness of SGLT2i in patients with T2DM in real-world setting.
METHODS
METHODS
This was a prospective observational longitudinal study involving consecutive patients with T2DM, initiated on SGLT2i from 1 April 2015 to 31 March 2016. The adverse effects and metabolic parameters were evaluated at 3 monthly intervals up to 1 year.
RESULTS
RESULTS
Total 486 patients were initiated on SGLT2i. At baseline, mean age, glycosylated haemoglobin (HbA1c), and weight was 51.03 ± 9.82 years, 8.76 ± 1.59%, and 89.32 ± 16.04 kg, respectively. Data of 388 patients were available at 6 months of follow-up for analysis of adverse effects profile. About 38.6% patients experienced adverse effects. Genitourinary tract infection was the most common adverse effect (20.6%) followed by generalized weakness (10.5%). Significant reduction in mean weight and HbA1c reduction seen at 6 months (
CONCLUSION
CONCLUSIONS
In this real-world study of patients with T2DM living in hot climate, use of SGLT2i was associated with adverse effects in higher proportion of patients than those reported in clinical trials, but effectiveness was comparable. Patient guidance regarding adequate hydration and hygiene can maximize the benefits of this promising class of drugs.
Identifiants
pubmed: 31016153
doi: 10.4103/ijem.IJEM_566_18
pii: IJEM-23-50
pmc: PMC6446693
doi:
Types de publication
Journal Article
Langues
eng
Pagination
50-55Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Pflugers Arch. 2004 Feb;447(5):510-8
pubmed: 12748858
N Engl J Med. 2008 Jun 12;358(24):2560-72
pubmed: 18539916
Clin Pharmacol Ther. 2009 May;85(5):520-6
pubmed: 19129748
Kidney Int. 2009 Jun;75(12):1272-1277
pubmed: 19357717
Lancet. 2010 Jun 26;375(9733):2223-33
pubmed: 20609968
Ann Intern Med. 2011 May 17;154(10):672-9
pubmed: 21576535
Diabetes. 2012 Sep;61(9):2199-204
pubmed: 22923645
Diabetes Care. 2013 Sep;36(9):2508-15
pubmed: 23564919
Lancet. 2013 Sep 14;382(9896):941-50
pubmed: 23850055
Ann Intern Med. 2013 Aug 20;159(4):262-74
pubmed: 24026259
J Clin Hypertens (Greenwich). 2014 Dec;16(12):875-82
pubmed: 25329038
Diabetes Care. 2015 Mar;38(3):365-72
pubmed: 25592197
Diabetes Care. 2015 Nov;38(11):2009-17
pubmed: 26246458
Diabetes Ther. 2016 Jun;7(2):269-78
pubmed: 26984361
Clin Invest Med. 2016 Apr 02;39(2):E48-62
pubmed: 27040861
J Diabetes Investig. 2017 Mar;8(2):227-234
pubmed: 27549920
Int J Clin Pract. 2016 Sep;70(9):775-85
pubmed: 27600862
Diabetes Care. 2017 Feb;40(2):201-209
pubmed: 27913576
Eur Rev Med Pharmacol Sci. 2017 Jan;21(1):199-211
pubmed: 28121337
Diabetes Ther. 2017 Apr;8(2):365-376
pubmed: 28324484
Circulation. 2017 Jul 18;136(3):249-259
pubmed: 28522450
Sci Rep. 2017 Jun 6;7(1):2824
pubmed: 28588220
J Diabetes Metab Disord. 2017 Jun 30;16:27
pubmed: 28680862
Diabetes Care. 2018 Jan;41(Suppl 1):S73-S85
pubmed: 29222379
Physiol Rev. 1994 Oct;74(4):993-1026
pubmed: 7938229
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976